We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company
News

GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company

GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company
News

GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GlaxoSmithKline and Pfizer Announce Agreement to Create a Specialist HIV Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GlaxoSmithKline plc (GSK) and Pfizer Inc (PFE) have announced they have entered into an agreement to create a new world-leading HIV company focused solely on research, development and commercialization of HIV medicines.

The new HIV business will be more sustainable and broader in scope than either company’s individually, and will hold a 19% share of the growing market. GSK will initially hold an 85% equity interest in the new company and Pfizer will hold 15%.

According to collaborators, the new company will have a broad product portfolio of 11 marketed products including therapies such as Combivir, Kivexa and Selzentry/Celsentri. Based on 2008 pro-forma results, this combined portfolio generated sales of approximately £1.6 billion and these revenues will provide the new company with financial stability and support investment in its pipeline.

The clear focus of the new business will be to invest in research and development of HIV treatments and formulations that improve adherence and overcome resistance to the virus.

The company will have a pipeline of 6 targeted medicines, including 4 compounds in phase II development. Altogether, the new company will have 17 molecules at its disposal to develop in fixed-dose combinations as possible new HIV treatments. The new company will contract R&D services directly from GSK and Pfizer to develop these medicines.

The new company will also invest in early-stage research and discovery of HIV medicines, and will benefit from a new Research Alliance Agreement with GSK and Pfizer.

Under this new alliance, GSK and Pfizer will continue to conduct discovery research and development into HIV medicines and the new company will invest in this activity and will have exclusive rights of first negotiation in relation to any new HIV-related medicine developed by either GSK or Pfizer.
Advertisement